Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company SyneuRx International Taiwan Corp.
DescriptionUndisclosed therapy
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II/III
Standard IndicationSchizophrenia
Indication DetailsTreat adolescent schizophrenia
Regulatory Designation U.S. - Orphan Drug (Treat adolescent schizophrenia)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today